Importantly, treatment with anti-IL-1β antibody and/or blockade of activation/assembly of NLRP3 inflammasome using NLRP3-specific inhibitor remarkably ameliorates fungi-induced CS-resistant type 2 immune responses. This evidence concerns the gene NLRP3 and Cowden syndrome 1.